Babylon Delivers Massive Growth and Adjusted EBITDA Margin Improvement in the First Quarter of 2022 and Raises 2022 Revenue Guidance
Babylon Holdings Limited (NYSE:BBLN) reported first-quarter 2022 revenue of $266.4 million, a 274% increase year-over-year, driven by an 805% rise in value-based care revenue. The company raised its 2022 revenue guidance to $1 billion or more, anticipating continued growth from U.S. expansions. Despite a reported loss of $91.4 million, adjusted EBITDA improved significantly. Babylon also expanded its U.S. value-based care membership by 63%, surpassing 270,000 members. The company aims for profitability by 2025, with plans for margin enhancements.
- First-quarter revenue increased by 274% to $266.4 million.
- Value-based care revenue surged by 805% to $246.6 million.
- 2022 revenue guidance raised to $1 billion or greater.
- 63% growth in U.S. value-based care members to over 270,000.
- Adjusted EBITDA margin improved significantly, targeting -29.5% for 2022.
- Loss for the period totaled $91.4 million, worse than the previous year.
- Adjusted EBITDA remains negative at -$72.2 million.
-
First quarter 2022 revenue grew over 3.5x year-over-year to
$266 million -
Increasing 2022 guidance for revenue to
$1.0 billion - Adjusted EBITDA Margin of (27)% for the quarter, ahead of previous full-year 2022 guidance of (30)%
-
U.S. value-based care members grew by63% from Q4 2021 to a total of more than 270,000 members
“Babylon has started 2022 with as much momentum as we finished 2021,” said
First Quarter Financial Results and Operating Metrics Summary
Comparison of the following financial and operating metrics for the three months ended
-
Total revenue was
$266.4 million $71.3 million 274% . This was primarily driven by the growth in value-based care (“VBC”) revenue, which increased by805% year-over-year to$246.6 million -
Loss for the period totaled
$91.4 million $10.8 million $24.8 million -
Clinical Care Delivery Expense increased year-over-year, from
$11.8 million $23.9 million 17% to9% demonstrating operational leverage across our network. -
Adjusted EBITDA totaled
$(72.2) million $(4.6) million $24.8 million -
At the beginning of 2022, we added over 100,000 new
U.S. VBC Members. The breakout ofU.S. VBC Members by health insurance program type is shown below:
% of Total |
|
|
|
Medicaid |
|
|
|
Medicare |
|
|
|
Commercial |
|
|
|
Total |
66,000 |
167,000 |
271,000 |
Adjusted EBITDA and Adjusted EBITDA Margin are non‐IFRS measures. An explanation of non‐IFRS measures, reconciliation of Adjusted EBITDA to the most comparable IFRS measure, Loss for the period, and calculations of IFRS Loss for the Period Margin and Adjusted EBITDA Margin have been provided at the end of this press release.
Recent Highlights
-
Achieved year-over-year 3.5x growth in revenue and over 4x growth in
U.S. VBC Members in the first quarter of 2022. Total revenue for the quarter exceeded$266 million -
Ramped up to engage members significantly faster in two new
U.S. VBC deals which launched in Q4 2021, with weekly high-risk sign up rates 4-5x faster inGeorgia and 8-10x faster inMississippi since launch than our first VBC contracts inMissouri andNew York 3. -
Added over 100,000
U.S. VBC Members in Q1 via three new VBC contract launches, growing to over 270,000 totalU.S. VBC members as ofMarch 31, 2022 . - Managed care for over 440,000 members globally2 at the end of the quarter.
-
Improved diversification of VBC membership through a more than 2.5x increase in our Medicare population from Q4 2021 driven by our partnership with a Direct Contracting Entity as part of the CMS Direct Contracting Model, where Babylon provides crucial care management services to Medicare beneficiaries in
California in a value-based care arrangement. - By leveraging our new Health Graph data platform, we can now automate the creation of B360 member eligibility profiles allowing us to effectively prioritize our population outreach efforts and inform deep member understanding and proactive care management.
-
Closed increased debt funding for
$100 million AlbaCore Capital Group which is focused on ESG investing. We received funds at the end ofMarch 2022 giving a cash and cash equivalents balance of$275.0 million March 31, 2022 .
| __________________ | ||
1 Rounded to nearest thousand. “U.S. VBC Members” means individuals who are covered by one of our |
||
2 “Global managed care members” means individuals globally who are covered by one of our value-based care agreements or other risk-based agreements with a health plan, healthcare provider or a government body (including |
||
3 High-risk sign up rates since launch in |
FY 2022 Financial Guidance
For the twelve months ending
The Company expects to see a continued improvement in Adjusted EBITDA Margin, and is updating guidance of Adjusted EBITDA loss for 2022 from (30)% of revenue to no greater than
These statements are forward-looking and actual results may differ materially. Please refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. We are not able to reconcile either projected 2022 Adjusted EBITDA loss or 2022 Adjusted EBITDA Margin to its most directly comparable IFRS measure as we are not able to forecast IFRS Loss on a forward-looking basis without unreasonable efforts due to the high variability and difficulty in predicting certain items that affect IFRS Loss for the period, including, but not limited to, impairment expense, share-based compensation, foreign exchange gains or losses and gains and losses on sale of subsidiaries. Adjusted EBITDA should not be used to predict IFRS Loss as the difference between the two measures is variable and may be significant.
First Quarter 2022 Earnings Conference Call
Babylon will host a conference call to discuss first quarter 2022 results on
Capital Markets Day -
Babylon will host a Capital Markets Day on
Additional Notes
Adjusted EBITDA and Adjusted EBITDA Margin are non‐IFRS measures. An explanation of non‐IFRS measures, a reconciliation of IFRS Loss for the period, the most directly comparable IFRS measure to Adjusted EBITDA, and calculation of IFRS Loss for the Period Margin and Adjusted EBITDA Margin, the most directly comparable IFRS measure, to Adjusted EBITDA Margin, have been provided at the end of this press release.
Accompanying supplemental information will be posted to the Investor Relations section of Babylon’s web site at https://ir.babylonhealth.com.
About Babylon
Babylon is one of the world’s fastest growing digital healthcare companies whose mission is to make high-quality healthcare accessible and affordable for every person on Earth.
Babylon is re-engineering how people engage with their care at every step of the healthcare continuum. By flipping the model from reactive sick care to proactive healthcare through the devices people already own, it offers millions of people globally ongoing, always-on care. Babylon has already shown that in environments as diverse as the developed
Founded in 2013, Babylon’s technology and clinical services is supporting a global patient network across 15 countries, and is capable of operating in 16 languages. And through a combination of its value-based care model, Babylon 360, and its work in primary care through
Babylon is also working with governments, health providers, employers and insurers across the globe to provide them with a new infrastructure that any partner can use to deliver high-quality healthcare with lower costs and better outcomes. For more information, please visit www.babylonhealth.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, without limitation, information concerning Babylon’s possible or assumed future results of operations, business strategies, debt levels, competitive position, industry environment and potential growth opportunities.
These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of Babylon’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to our future financial and operating results and that we may require additional financing; uncertainties related to our ability to continue as a going concern; the growth of our business and organization; our failure to compete successfully; our ability to renew contracts with existing customers, and risks of contract renewals at lower fee levels, or significant reductions in members, pricing or premiums under our contracts due to factors outside our control; our dependence on our relationships with physician-owned entities; our ability to maintain and expand a network of qualified providers; our ability to increase engagement of individual members or realize the member healthcare cost savings that we expect; a significant portion of our revenue comes from a limited number of customers; the uncertainty and potential inadequacy of our claims liability estimates for medical costs and expenses; risks associated with estimating the amount and timing of revenue recognized under our licensing agreements and value-based care agreements with health plans; risks associated with our physician partners’ failure to accurately, timely and sufficiently document their services; risks associated with inaccurate or unsupportable information regarding risk adjustment scores of members in records and submissions to health plans; risks associated with reduction of reimbursement rates paid by third-party payers or federal or state healthcare programs; risks associated with regulatory proposals directed at containing or lowering the cost of healthcare, including the ACO REACH model; immaturity and volatility of the market for telemedicine and our unproven digital-first approach; our ability to develop and release new solutions and services; the impact of COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in
Babylon cautions that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, Babylon does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.
Table 1
Consolidated Statement of Profit and Loss and Other Comprehensive Loss (In USD thousands, except per share amounts, unaudited) |
|||||||
|
For the Three Months Ended |
||||||
|
2022 |
|
2021 |
||||
Revenue: |
|
|
|
||||
Value-based care |
|
246,575 |
|
|
|
27,259 |
|
Software licensing |
|
7,756 |
|
|
|
35,964 |
|
Clinical services |
|
12,115 |
|
|
|
8,070 |
|
Total revenue |
|
266,446 |
|
|
|
71,293 |
|
Clinical care delivery expense |
|
(23,927 |
) |
|
|
(11,823 |
) |
Claims expense |
|
(247,552 |
) |
|
|
(23,917 |
) |
Platform & application expenses |
|
(16,703 |
) |
|
|
(6,434 |
) |
Research & development expenses |
|
(10,057 |
) |
|
|
(10,390 |
) |
Sales, general & administrative expenses |
|
(58,310 |
) |
|
|
(31,479 |
) |
Operating loss |
|
(90,103 |
) |
|
|
(12,750 |
) |
Finance costs |
|
(6,628 |
) |
|
|
(992 |
) |
Finance income |
|
255 |
|
|
|
14 |
|
Change in fair value of warrant liabilities |
|
5,575 |
|
|
|
— |
|
Exchange loss |
|
(447 |
) |
|
|
(573 |
) |
Net finance expense |
|
(1,245 |
) |
|
|
(1,551 |
) |
Gain on sale of subsidiary |
|
— |
|
|
|
3,917 |
|
Share of loss of equity-accounted investees |
|
— |
|
|
|
(455 |
) |
Loss before taxation |
|
(91,348 |
) |
|
|
(10,839 |
) |
Tax provision |
|
(9 |
) |
|
|
(8 |
) |
Loss for the period |
|
(91,357 |
) |
|
|
(10,847 |
) |
Other comprehensive loss |
|
|
|
||||
Items that may be reclassified subsequently to profit or loss: |
|
|
|
||||
Currency translation differences |
|
(3,753 |
) |
|
|
(1,754 |
) |
Other comprehensive loss for the period, net of income tax |
|
(3,753 |
) |
|
|
(1,754 |
) |
Total comprehensive loss for the period |
|
(95,110 |
) |
|
|
(12,601 |
) |
Loss attributable to: |
|
|
|
||||
Equity holders of the parent |
|
(91,357 |
) |
|
|
(10,466 |
) |
Non-controlling interest |
|
— |
|
|
|
(381 |
) |
|
|
(91,357 |
) |
|
|
(10,847 |
) |
Total comprehensive loss attributable to: |
|
|
|
||||
Equity holders of the parent |
|
(95,110 |
) |
|
|
(12,220 |
) |
Non-controlling interest |
|
— |
|
|
|
(381 |
) |
|
|
(95,110 |
) |
|
|
(12,601 |
) |
Net loss per share, Basic and Diluted |
$ |
(0.24 |
) |
|
$ |
(0.04 |
) |
Table 2
Consolidated Statement of Cash Flows In USD thousands, unaudited) |
|||||
|
For the Three Months Ended |
||||
|
2022 |
|
2021 |
||
Cash flows from operating activities |
|
|
|
||
Loss for the period |
(91,357 |
) |
|
(10,847 |
) |
Adjustments to reconcile Loss for the year to net cash (provided by) used in operating activities: |
|
|
|
||
Finance costs |
6,628 |
|
|
992 |
|
Finance income |
(255 |
) |
|
(14 |
) |
Change in fair value of warrant liabilities |
(5,575 |
) |
|
— |
|
Depreciation and amortization |
9,458 |
|
|
5,848 |
|
Share-based compensation |
8,402 |
|
|
2,802 |
|
Taxation |
9 |
|
|
8 |
|
Exchange loss |
447 |
|
|
573 |
|
Share of loss of equity-accounted investees |
— |
|
|
455 |
|
Gain on sale of subsidiary |
— |
|
|
(3,917 |
) |
|
(72,243 |
) |
|
(4,100 |
) |
Working capital adjustments |
|
|
|
||
Increase in trade and other receivables |
126 |
|
|
(8,704 |
) |
Increase in trade and other payables |
3,160 |
|
|
34,304 |
|
Net cash (provided by) used in operating activities |
(68,957 |
) |
|
21,500 |
|
Cash flows from investing activities |
|
|
|
||
Capital expenditure |
(2,613 |
) |
|
(311 |
) |
Interest received |
255 |
|
|
14 |
|
Development costs capitalized |
(9,298 |
) |
|
(7,198 |
) |
Proceeds from sale of investment in subsidiary |
— |
|
|
2,213 |
|
Purchase of shares in associates and joint ventures |
— |
|
|
(2,000 |
) |
Net cash used in investing activities |
(11,656 |
) |
|
(7,282 |
) |
Cash flows from financing activities |
|
|
|
||
Proceeds from issuance of notes and warrants |
100,000 |
|
|
— |
|
Payment of equity and debt issuance costs |
(5,002 |
) |
|
— |
|
Other financing activities, net |
(1,538 |
) |
|
(482 |
) |
Principal payments on leases |
(460 |
) |
|
(1,520 |
) |
Interest paid |
(22 |
) |
|
(18 |
) |
Net cash provided by (used in) financing activities |
92,978 |
|
|
(2,020 |
) |
Net increase in cash and cash equivalents |
12,365 |
|
|
12,198 |
|
Cash and cash equivalents at |
262,581 |
|
|
101,757 |
|
Effect of movements in exchange rate on cash held |
32 |
|
|
(57 |
) |
Cash and cash equivalents at end of period |
274,978 |
|
|
113,898 |
|
Table 3
Consolidated Statement of Financial Position (In USD thousands, unaudited) |
|||||
|
|
|
|
||
ASSETS |
|
|
|
||
Non-current assets |
|
|
|
||
Right-of-use assets |
20,014 |
|
|
7,844 |
|
Property, plant and equipment |
25,694 |
|
|
24,990 |
|
|
93,655 |
|
|
93,678 |
|
Other intangible assets |
112,830 |
|
|
111,421 |
|
Total non-current assets |
252,193 |
|
|
237,933 |
|
Current assets |
|
|
|
||
Right-of-use assets |
5,454 |
|
|
3,999 |
|
Trade and other receivables |
27,981 |
|
|
24,119 |
|
Prepayments and contract assets |
21,971 |
|
|
26,000 |
|
Cash and cash equivalents |
274,978 |
|
|
262,581 |
|
Total current assets |
330,384 |
|
|
316,699 |
|
Total assets |
582,577 |
|
|
554,632 |
|
EQUITY AND LIABILITIES |
|
|
|
||
EQUITY |
|
|
|
||
Ordinary share capital |
16 |
|
|
16 |
|
Share premium |
923,093 |
|
|
922,897 |
|
Share-based payment reserve |
89,545 |
|
|
80,371 |
|
Retained earnings |
(929,343 |
) |
|
(837,986 |
) |
Foreign currency translation reserve |
(3,780 |
) |
|
(27 |
) |
Total capital and reserves |
79,531 |
|
|
165,271 |
|
Total equity |
79,531 |
|
|
165,271 |
|
LIABILITIES |
|
|
|
||
Non-current liabilities |
|
|
|
||
Loans and borrowings |
262,142 |
|
|
168,601 |
|
Contract liabilities |
63,763 |
|
|
70,396 |
|
Lease liabilities |
20,143 |
|
|
8,442 |
|
Deferred grant income |
6,134 |
|
|
7,236 |
|
Deferred tax liability |
1,016 |
|
|
1,019 |
|
Total non-current liabilities |
353,198 |
|
255,694 |
|
|
Current liabilities |
|
|
|
||
Trade and other payables |
25,198 |
|
|
22,687 |
|
Accruals and provisions |
37,886 |
|
|
36,855 |
|
Claims payable |
39,165 |
|
|
24,628 |
|
Contract liabilities |
22,663 |
|
|
23,786 |
|
Warrant liability |
17,971 |
|
|
20,128 |
|
Lease liabilities |
5,301 |
|
|
4,190 |
|
Deferred grant income |
1,664 |
|
|
1,208 |
|
Loans and borrowings |
— |
|
|
185 |
|
Total current liabilities |
149,848 |
|
133,667 |
|
|
Total liabilities |
503,046 |
|
389,361 |
|
|
Total liabilities and equity |
582,577 |
|
|
554,632 |
|
Table 4
Reconciliation of IFRS Loss for the Period to EBITDA and Adjusted EBITDA
and Calculations of IFRS Loss for the Period Margin and Adjusted EBITDA Margin
(In USD thousands, unaudited)
EBITDA is defined as profit (loss) for the period, adjusted for depreciation and amortization, finance costs and income, and tax provision or benefit. Adjusted EBITDA is defined as profit (loss) for the period, adjusted for depreciation and amortization, finance costs and income, tax provision or benefit, share-based compensation, change in fair value of warrant liabilities, gain on sale of subsidiary, and foreign exchange gains or losses. Loss for the period is the most directly comparable IFRS measure to Adjusted EBITDA. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Total revenue for the corresponding period. IFRS Loss for the Period Margin is the most directly comparable IFRS measure to Adjusted EBITDA Margin.
We believe that EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are useful metrics for investors to understand and evaluate our operating results and ongoing profitability because it permits investors to evaluate our recurring profitability from our ongoing operating activities.
EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin have certain limitations, and you should not consider them in isolation or as a substitute for analysis of our results of operations as reported under IFRS. We caution investors that amounts presented in accordance with our definitions of EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin may not be comparable to similar measures disclosed by other issuers, because some issuers calculate EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin differently or not at all, limiting their usefulness as direct comparative measures.
The following table presents a reconciliation of EBITDA and Adjusted EBITDA from the most directly comparable IFRS measure, Loss for the period, and the calculations of IFRS Loss for the Period Margin and Adjusted EBITDA Margin, for the three months ended
|
For the Three Months Ended |
||||
|
2022 |
|
2021 |
||
IFRS Loss for the period |
(91,357 |
) |
|
(10,847 |
) |
Adjustments to calculate EBITDA: |
|
|
|
||
Depreciation and amortization |
9,458 |
|
|
5,848 |
|
Finance costs and income |
6,373 |
|
|
978 |
|
Tax provision |
9 |
|
|
8 |
|
EBITDA |
(75,517 |
) |
|
(4,013 |
) |
Adjustments to calculate Adjusted EBITDA: |
|
|
|
||
Share-based compensation |
8,402 |
|
|
2,802 |
|
Change in fair value of warrant liabilities |
(5,575 |
) |
|
— |
|
Gain on sale of subsidiary |
— |
|
|
(3,917 |
) |
Exchange loss |
447 |
|
|
573 |
|
Adjusted EBITDA |
(72,243 |
) |
|
(4,555 |
) |
|
|
|
|
||
Total revenue |
266,446 |
|
|
71,293 |
|
IFRS Loss for the Period Margin |
(34 |
) % |
|
(15 |
) % |
Adjusted EBITDA Margin |
(27 |
) % |
|
(6 |
) % |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005152/en/
Media
press@babylonhealth.com
Investors
investors@babylonhealth.com
Source:
FAQ
What were Babylon Holdings Limited's Q1 2022 revenue figures?
How much did Babylon raise its revenue guidance for 2022?
What is the current adjusted EBITDA margin for Babylon in Q1 2022?
How many U.S. value-based care members does Babylon have as of March 31, 2022?
What was the net loss reported by Babylon in Q1 2022?
